Semaglutide,
reconsidered.
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and later approved for weight management (Wegovy).
Semaglutide binds to GLP-1 receptors in the brain (hypothalamus) to reduce appetite and food intake. It slows gastric emptying, increases insulin secretion in response to glucose, and suppresses glucagon release. The fatty acid modification (C-18 acylation) extends its half-life to ~7 days by promoting albumin binding.
Essential profiles
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly.
Liraglutide
Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk, FDA-approved as Victoza for type 2 diabetes (2010) and Saxenda for weight management (2014).
Melanotan II
Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH) that stimulates melanogenesis (skin tanning) and has secondary effects on sexual arousal and appetite suppression.
Browse by category
Further dispatches
BPC-157
BPC-157 is a pentadecapeptide (15 amino acids) derived from human gastric juice.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to produce and release growth hormone.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone (GH).
PT-141
PT-141 (bremelanotide) is a melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Peptide research deserves a reference worthy of its complexity — neither sensationalized by clickbait nor buried in inaccessible jargon.